Conversely, anhidrosis, or reduced or absent sweating, is less common but may be experienced in the feet or legs of people with diabetic neuropathy. Treatment of excessive sweating depends on the ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

Ionis Pharmaceuticals IONS announced that the European Commission (“EC”) has approved Wainzua (eplontersen) for treating ...

Damage or injury to nerves causes a painful condition called neuropathy. This article reviews the safety and evidence behind ...

Autoimmune diseases like Sjögren’s syndrome, lupus, rheumatoid arthritis, Guillain-Barré syndrome, chronic inflammatory ...

A note by the health ministry on the drugs alert stated that the failure is specific to the drug products of the batch tested by the government laboratories and does not warrant any concerns about ...

Doctors refer to hair loss that occurs as a side effect of medication as drug-induced alopecia. Hair loss can be a side effect of many different medications, such as those for chemotherapy.

If you experience symptomatic gallstones, there are a number of different treatment options available. Your exact course of treatment will depend on your symptoms and the characteristics of the ...

For people with type 2 diabetes, those on glucose-lowering medications or insulin are at the most risk for low blood sugar. It is important to check with your doctor if you are having any symptoms ...

Patients on semaglutide (Ozempic, Wegovy) had a 32% increased relative risk of developing nonarteritic anterior ischemic optic neuropathy ... other GLP-1 diabetes medications.

Jenburkt Pharmaceuticals supports NIMHANS' Neuropathy Lecture Series to enhance diagnosis and treatment for better patient outcomes. Neuropathy, or nerve damage, often remains undiagnosed or ...

Assessment of cardiovascular (CV) toxicity by providers in advanced prostate cancer (PCa) patients (pts) on novel hormonal therapy (NHT). This is an ASCO Meeting Abstract from the 2025 ASCO ...